3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinosarcoma
1
Interventions
Gemcitabine
5
Docetaxel
4
tislelizumab
3
Bortezomib
3
spartalizumab
2
pembrolizumab
2
Nivolumab
2
Irinotecan
2
Filgrastim
2
Cisplatin
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
tinostamustine
1
talazoparib
1
surufatinib
1
regorafenib
1
pazopanib
1
pamiparib
1
liposomal doxorubicin
1
isophosphamide mustard
1
futibatinib
1
etoposide phosphate
1
entinostat
1
cc-486
1
cabozantinib
1
atezolizumab
1
anlotinib
1
Vinorelbine
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
trastuzumab deruxtecan
×
Sarcoma
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled